Borderline ovarian tumors represent a heterogeneous group of noninvasive tumors of uncertain malignant potential with characteristic histology. They occur in younger women, are present at an early stage, and have a favorable prognosis, but symptomatic recurrence and death may be found as long as 20 years after therapy in some patients. The molecular changes in borderline ovarian tumors indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas). The pathological stage of disease and subclassification of extraovarian disease into invasive and noninvasive implants, together with the presence of postoperative macroscopic residual disease, appear to be the major predictor of recurrence and survival. However, it should be emphasized that the most important negative prognostic factor for recurrence is just the use of conservative surgery, but without any impact on patient survival because most recurrent diseases are of the borderline type-easily curable and with an excellent prognosis. Borderline tumors are difficult masses to correctly preoperatively diagnose using imaging methods because their macroscopic features may overlap with invasive and benign ovarian tumors. Over the past several decades, surgical therapy has shifted from a radical approach to more conservative treatment; however, oncologic safety must always be balanced. Follow-up is essential using routine ultrasound imaging, with special attention paid to the remaining ovary in conservatively treated patients. Current literature on this topic leads to a number of controversies that will be discussed thoroughly in this article, with the aim to provide recommendations for the clinical management of these patients.

Gynecological Oncology Center Department of Obstetrics and Gynecology Apolinaska 18 120 00 Prague Czech Republic

Zobrazit více v PubMed

Sutton GP. Ovarian tumors of low malignant potential. In: Rubin SC, Sutton GP, editors. Ovarian Cancer. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 399–417.

Katsube Y, Berg JW, Silverberg SG. Epidemiologic pathology of ovarian tumors: A histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol. 1982;1:3–16. PubMed

Skirnisdottir I, Garmo H, Wilander E, et al. Borderline ovarian tumors in Sweden 1960–2005: Trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008;123:1897–1901. PubMed

Sherman ME, Berman J, Birrer MJ, et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol. 2004;35:961–970. PubMed

Bjorge T, Engeland A, Hansen S, et al. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954–1993. Int J Cancer. 1997;71:780–786. PubMed

Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S161–S192. PubMed

Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371:303–314. PubMed

van Leeuwen FE, Klip H, Mooij TM, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456–3465. PubMed PMC

du Bois A, Ewald-Riegler N, du Bois O, et al. Borderline tumors of the ovary: A systematic review. Geburtsh Frauenheilk. 2009;69:807–833.

Sherman ME, Mink PJ, Curtis R, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: A population-based analysis. Cancer. 2004;100:1045–1052. PubMed

Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: A review. Gynecol Oncol. 2006;100:185–191. PubMed

Trope C, Davidson B, Paulsen T, et al. Diagnosis and treatment of borderline ovarian neoplasms “the state of the art.”. Eur J Gynaecol Oncol. 2009;30:471–482. PubMed

Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S29–S42. PubMed

Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer. 2006;42:149–158. PubMed

Burger CW, Prinssen HM, Baak JP, et al. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer. 2000;10:181–197. PubMed

Bjorge T, Lie AK, Hovig E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: A nested case-control study. Br J Cancer. 2004;91:1829–1834. PubMed PMC

Gotlieb WH, Chetrit A, Menczer J, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol. 2005;97:780–783. PubMed

Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631–650. PubMed

Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1204–1211. PubMed

Fathalla MF. Incessant ovulation: A factor in ovarian neoplasia? Lancet. 1971;2:163. PubMed

Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: Results of a Swedish case-control study. Gynecol Oncol. 2001;83:575–585. PubMed

Kumle M, Weiderpass E, Braaten T, et al. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer. 2004;90:1386–1391. PubMed PMC

Huusom LD, Frederiksen K, Hogdall EV, et al. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: A Danish case-control study. Cancer Causes Control. 2006;17:821–829. PubMed

Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol. 2002;155:217–224. PubMed

Olsen CM, Green AC, Nagle CM, et al. Epithelial ovarian cancer: Testing the “androgens hypothesis.”. Endocr Relat Cancer. 2008;15:1061–1068. PubMed

Seidman JD, Cho KR, Ronnett BM, et al. Surface epithelial tumors of the ovary. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein′s Pathology of the Female Genital Tract. 6th ed. New York: Springer Science +Business Medica; 2011. pp. 680–772.

Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39:157–158. PubMed

Fiegl H, Windbichler G, Mueller-Holzner E, et al. HOXA11 DNA methylation: A novel prognostic biomarker in ovarian cancer. Int J Cancer. 2008;123:725–729. PubMed

Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(suppl 2):S19–S32. PubMed

Shih Ie M, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin Cancer Res. 2005;11:7273–7279. PubMed

Shih Ie M, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511–1518. PubMed PMC

Lee KR, Tavassoli FA, Prat J, et al. Tumours of the ovary and peritoneum. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003. pp. 113–202.

Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol. 1996;20:1331–1345. PubMed

Seidman JD, Kurman RJ. Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539–557. PubMed

Seidman JD, Khedmati F, Yemelyanova AV. Ovarial low grade serous neoplasm: Evaluation of sampling recommendations based on tumors expected to have invasion (those with peritoneal invasive low grade serous carcinoma (invasive implants)) Mod Pathol. 2009;22(suppl 1) Abstract 236A.

Seidman JD, Soslow RA, Vang R, et al. Borderline ovarian tumors: Diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol. 2004;35:918–933. PubMed

McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): Pathology, prognosis, and proposed classification. Am J Surg Pathol. 2006;30:614–624. PubMed

Chang SJ, Ryu HS, Chang KH, et al. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet Gynecol Scand. 2008;87:476–481. PubMed

Cuatrecasas M, Villanueva A, Matias-Guiu X, et al. K-ras mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer. 1997;79:1581–1586. PubMed

Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: Atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529–1541. PubMed

Meriden Z, Yemelyanova AV, Vang R, et al. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: Analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol. 2011;35:276–288. PubMed

Ronnett BM, Kajdacsy-Balla A, Gilks CB, et al. Mucinous borderline ovarian tumors: Points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol. 2004;35:949–960. PubMed

McKenney JK, Soslow RA, Longacre TA. Ovarian mature teratomas with mucinous epithelial neoplasms: Morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol. 2008;32:645–655. PubMed

Ronnett BM, Seidman JD. Mucinous tumors arising in ovarian mature cystic teratomas: Relationship to the clinical syndrome of pseudomyxoma peritonei. Am J Surg Pathol. 2003;27:650–657. PubMed

Abu-Rustum NR, Ramirez PT. Surgical postgraduate courses. Gynecologic oncology. Gynecol Oncol. 2007;104(2 suppl 1):1. PubMed

Gershenson DM, Silva EG, Levy L, et al. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer. 1998;82:1096–1103. PubMed

Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–368. PubMed

Gershenson DM, Silva EG, Tortolero-Luna G, et al. Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer. 1998;83:2157–2163. PubMed

Kane A, Uzan C, Rey A, et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist. 2009;14:591–600. PubMed

Seidman AJ, Varallo MR. Micropapillary serous carcinoma: The solution to the ovarian borderline tumor conundrum. Pathol Case Rev. 2007;12:136–142.

Prat J, De Nictolis M. Serous borderline tumors of the ovary: A long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111–1128. PubMed

McKenney JK, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): A reevaluation of the concept of stromal microinvasion. Am J Surg Pathol. 2006;30:1209–1221. PubMed

Dube V, Roy M, Plante M, et al. Mucinous ovarian tumors of Mullerian-type: An analysis of 17 cases including borderline tumors and intraepithelial, microinvasive, and invasive carcinomas. Int J Gynecol Pathol. 2005;24:138–146. PubMed

Rodriguez IM, Irving JA, Prat J. Endocervical-like mucinous borderline tumors of the ovary: A clinicopathologic analysis of 31 cases. Am J Surg Pathol. 2004;28:1311–1318. PubMed

Kaern J, Trope C, Kjorstad KE, et al. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol. 1990;38:452–457. PubMed

Meyer JS, Gersell DJ, Yim S. Cell proliferation in ovarian carcinoma: Superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate. Gynecol Oncol. 2001;81:466–476. PubMed

Verbruggen MB, van Diest PJ, Baak JP, et al. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: A prospective study. Int J Gynecol Pathol. 2009;28:35–40. PubMed

Menczer J, Chetrit A, Sadetzki S. The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecol Oncol. 2012;125:372–375. PubMed

Ramirez PT, Milam MR. Laparoscopic extraperitoneal paraaortic lymphadenectomy in patients with locally advanced cervical cancer. Gynecol Oncol. 2007;104(2 suppl 1):9–12. PubMed

Bristow RE, Gossett DR, Shook DR, et al. Micropapillary serous ovarian carcinoma: Surgical management and clinical outcome. Gynecol Oncol. 2002;86:163–170. PubMed

Fauvet R, Boccara J, Dufournet C, et al. Restaging surgery for women with borderline ovarian tumors: Results of a French multicenter study. Cancer. 2004;100:1145–1151. PubMed

Zapardiel I, Rosenberg P, Peiretti M, et al. The role of restaging borderline ovarian tumors: Single institution experience and review of the literature. Gynecol Oncol. 2010;119:274–277. PubMed

Winter WE, 3rd, Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol. 2002;100:671–676. PubMed

Slomovitz BM, Sun CC, Frumovitz M, et al. Are women ready for the HPV vaccine? Gynecol Oncol. 2006;103:151–154. PubMed

Ramirez PT, Slomovitz BM, McQuinn L, et al. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol. 2006;103:888–890. PubMed

Koskas M, Uzan C, Gouy S, et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma) Ann Surg Oncol. 2011;18:40–48. PubMed

Slomovitz BM, Ramirez PT, Frumovitz M, et al. Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol. 2006;102:534–536. PubMed

Ramirez PT, Slomovitz BM, Soliman PT, et al. Total laparoscopic radical hysterectomy and lymphadenectomy: the MD Anderson Cancer Center experience. Gynecol Oncol. 2006;102:252–255. PubMed

Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: A large population-based study. Gynecol Oncol. 2006;103:841–847. PubMed

Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study. J Clin Oncol. 2001;19:2658–2664. PubMed

Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: Are they ever malignant? Int J Gynecol Pathol. 1993;12:120–127. PubMed

Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol. 2003;14:592–598. PubMed

Camatte S, Morice P, Pautier P, et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG. 2002;109:376–380. PubMed

De Iaco P, Ferrero A, Rosati F, et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur J Surg Oncol. 2009;35:643–648. PubMed

Fauvet R, Boccara J, Dufournet C, et al. Laparoscopic management of borderline ovarian tumors: Results of a French multicenter study. Ann Oncol. 2005;16:403–410. PubMed

Trope C, Kaern J, Vergote IB, et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol. 1993;51:236–243. PubMed

Valentin L. Prospective cross-validation of Doppler ultrasound examination and gray-scale ultrasound imaging for discrimination of benign and malignant pelvic masses. Ultrasound Obstet Gynecol. 1999;14:273–283. PubMed

Valentin L, Hagen B, Tingulstad S, et al. Comparison of “pattern recognition” and logistic regression models for discrimination between benign and malignant pelvic masses: A prospective cross validation. Ultrasound Obstet Gynecol. 2001;18:357–365. PubMed

Timmerman D, Schwarzler P, Collins WP, et al. Subjective assessment of adnexal masses with the use of ultrasonography: An analysis of interobserver variability and experience. Ultrasound Obstet Gynecol. 1999;13:11–16. PubMed

Valentin L, Ameye L, Jurkovic D, et al. Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound Obstet Gynecol. 2006;27:438–444. PubMed

Valentin L, Ameye L, Testa A, et al. Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol. 2006;102:41–48. PubMed

Yazbek J, Ameye L, Timmerman D, et al. Use of ultrasound pattern recognition by expert operators to identify borderline ovarian tumors: A study of diagnostic performance and interobserver agreement. Ultrasound Obstet Gynecol. 2010;35:84–88. PubMed

Fruscella E, Testa AC, Ferrandina G, et al. Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound Obstet Gynecol. 2005;26:644–650. PubMed

Yazbek J, Raju KS, Ben-Nagi J, et al. Accuracy of ultrasound subjective “pattern recognition” for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol. 2007;29:489–495. PubMed

Exacoustos C, Romanini ME, Rinaldo D, et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol. 2005;25:50–59. PubMed

Pascual MA, Tresserra F, Grases PJ, et al. Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings. J Clin Ultrasound. 2002;30:76–82. PubMed

Sokalska A, Timmerman D, Testa AC, et al. Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound Obstet Gynecol. 2009;34:462–470. PubMed

Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol. 2004;18:71–89. PubMed

Van Holsbeke C, Van Calster B, Guerriero S, et al. Endometriomas: Their ultrasound characteristics. Ultrasound Obstet Gynecol. 2010;35:730–740. PubMed

Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol. 2010;34:433–443. PubMed PMC

Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Ultrasound Obstet Gynecol. 1999;14:338–347. PubMed

Fischerova D, Franchi D, Testa A, et al. Ultrasound in diagnosis of new and borderline ovarian tumors. Ultrasound Obstet Gynecol. 2010;36(suppl. 1) Abstract OC01.03. PubMed

Testa AC, Timmerman D, Exacoustos C, et al. The role of CnTI-SonoVue in the diagnosis of ovarian masses with papillary projections: A preliminary study. Ultrasound Obstet Gynecol. 2007;29:512–516. PubMed

Testa AC, Timmerman D, Van Belle V, et al. Intravenous contrast ultrasound examination using contrast-tuned imaging (CnTI) and the contrast medium SonoVue for discrimination between benign and malignant adnexal masses with solid components. Ultrasound Obstet Gynecol. 2009;34:699–710. PubMed

Alcazar JL, Jurado M. Three-dimensional ultrasound for assessing women with gynecological cancer: A systematic review. Gynecol Oncol. 2011;120:340–346. PubMed

Testa AC, Ludovisi M, Mascilini F, et al. Ultrasound evaluation of intra-abdominal sites of disease to predict likelihood of suboptimal cytoreduction in advanced ovarian cancer: A prospective study. Ultrasound Obstet Gynecol. 2012;39:99–105. PubMed

Fischerova D. Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: A review. Ultrasound Obstet Gynecol. 2011;38:246–266. PubMed

Shaaban A, Rezvani M. Ovarian cancer: Detection and radiologic staging. Clin Obstet Gynecol. 2009;52:73–93. PubMed

Valentin L. Imaging in gynecology. Best Pract Res Clin Obstet Gynaecol. 2006;20:881–906. PubMed

deSouza NM, O'Neill R, McIndoe GA, et al. Borderline tumors of the ovary: CT and MRI features and tumor markers in differentiation from stage I disease. AJR Am J Roentgenol. 2005;184:999–1003. PubMed

Risum S, Hogdall C, Loft A, et al. The diagnostic value of PET/CT for primary ovarian cancer: A prospective study. Gynecol Oncol. 2007;105:145–149. PubMed

Jung DC, Choi HJ, Ju W, et al. Discordant MRI/FDG-PET imaging for the diagnosis of borderline ovarian tumors. Int J Gynecol Cancer. 2008;18:637–641. PubMed

Redman C, Duffy S, Bromham N, et al. Recognition and initial management of ovarian cancer: summary of NICE guidance. BMJ. 2011;342:d2073. PubMed

Van Gorp T, Veldman J, Van Calster B, et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. Eur J Cancer. 2012;48:1649–1656. PubMed

Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97:922–929. PubMed

Van Holsbeke C, Van Calster B, Bourne T, et al. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clin Cancer Res. 2012;18:815–825. PubMed

Valentin L, Ameye L, Savelli L, et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound Obstet Gynecol. 2011;38:456–465. PubMed

Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: Prospective validation by IOTA group. BMJ. 2010;341:c6839. PubMed PMC

Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol. 2000;19:69–75. PubMed

Uzan C, Kane A, Rey A, et al. Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary. Ann Oncol. 2010;21:55–60. PubMed

Trillsch F, Mahner S, Ruetzel J, et al. Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther. 2010;10:1115–1124. PubMed

Franchi D, Boveri S, Fruscio R, et al. Imaging in gynecological disease: Ultrasound characteristics of ovarian borderline tumor recurrence. Ultrasound Obstet Gynecol. 2012 Aug 1; [Epub ahead of print], doi: 10.1002/uog.12276. PubMed DOI

Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: A follow-up study of 35 cases. Obstet Gynecol. 1988;72:775–781. PubMed

Poncelet C, Fauvet R, Boccara J, et al. Recurrence after cystectomy for borderline ovarian tumors: Results of a French multicenter study. Ann Surg Oncol. 2006;13:565–571. PubMed

Tempfer CB, Polterauer S, Bentz EK, et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: A retrospective analysis of 96 cases and review of the literature. Gynecol Oncol. 2007;107:248–252. PubMed

Romagnolo C, Gadducci A, Sartori E, et al. Management of borderline ovarian tumors: Results of an Italian multicenter study. Gynecol Oncol. 2006;101:255–260. PubMed

Deffieux X, Morice P, Camatte S, et al. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol Oncol. 2005;97:84–89. PubMed

Abu-Jawdeh GM, Jacobs TW, Niloff J, et al. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 1996;60(2):301–307. PubMed

Lee EJ, Deavers MT, Hughes JI, et al. Metastasis to sigmoid colon mucosa and submucosa from serous borderline ovarian tumor: Response to hormone therapy. Int J Gynecol Cancer. 2006;16(suppl 1):295–299. PubMed

Hua K, Feng W, Cao Q, et al. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer. Int J Oncol. 2008;33:959–967. PubMed

Fauvet R, Poncelet C, Boccara J, et al. Fertility after conservative treatment for borderline ovarian tumors: A French multicenter study. Fertil Steril. 2005;83:284–290. PubMed

Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360:902–911. PubMed PMC

Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol. 2002;99:3–10. PubMed

Bostwick DG, Tazelaar HD, Ballon SC, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer. 1986;58:2052–2065. PubMed

Silva EG, Gershenson DM, Malpica A, et al. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol. 2006;30:1367–1371. PubMed

Benedet JL, Bender H, Jones H, 3rd, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209–262. PubMed

Zanetta G, Rota S, Lissoni A, et al. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol. 2001;81:63–66. PubMed

Papadimitriou DS, Martin-Hirsch P, Kitchener HC, et al. Recurrent borderline ovarian tumours after conservative management in women wishing to retain their fertility. Eur J Gynaecol Oncol. 1999;20:94–97. PubMed

Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population